Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE

US Bancorp DE lowered its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,522 shares of the biotechnology company’s stock after selling 5,601 shares during the quarter. US Bancorp DE’s holdings in Arrowhead Pharmaceuticals were worth $649,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARWR. R Squared Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $38,000. Van ECK Associates Corp boosted its position in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,250 shares in the last quarter. KBC Group NV boosted its position in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $149,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $205,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, COO Patrick O’brien sold 29,184 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $578,426.88. Following the transaction, the chief operating officer now directly owns 535,201 shares in the company, valued at $10,607,683.82. This trade represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now owns 44,125 shares in the company, valued at $966,337.50. This trade represents a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 280,765 shares of company stock worth $5,227,313. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on ARWR shares. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. Piper Sandler decreased their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Trading Down 1.0 %

Shares of ARWR stock opened at $15.06 on Wednesday. The firm has a 50-day moving average price of $19.24 and a 200 day moving average price of $20.35. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $14.23 and a twelve month high of $30.41. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -2.91 and a beta of 0.92. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.